AI-generated summary
The authors report a randomized, double-blind, placebo-controlled pilot study of combined transcranial and intra-oral laser photobiomodulation in 22 people with Parkinson's disease over four weeks. No physical or cognitive measures showed statistically significant change, though some tests showed possible positive trends and a placebo effect was noted. The authors suggest longer or more frequent treatment may be needed.
- Participants
- 22
- Who or what was studied
- People with Parkinson's disease
- Wavelengths
- 904 nm
- Limits stated in the abstract
- The abstract describes a small pilot study with no statistically significant outcome changes and an unclear placebo effect, so the findings are preliminary.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 904 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Placebo-controlled, Pilot study, Montreal Cognitive Assessment, Placebo effect, Laser, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.